System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Rabbit Polyclonal to MEK 1/2 / MAPKK 1/2

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-508-C050 purified 0.05 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


MEK (MAPKK, kinase of mitogen-activated protein kinase) is the medium one of three components of MAP kinase cascade – an important signaling pathway that regulates cell growth and differentiation. Raf (MAPKKK) activates MEK 1 and 2 via phosphorylation of two serine residues (Ser218 and Ser222). Activated MEK 1/2 then acts as a dual specificity kinase phosphorylating both a threonine and a tyrosine residue on ERK (MAPK, mitogen-activated protein kinase). This phosphorylation of ERK by MEK 1/2 is a critical step in the MAP kinase cascade. Phosphorylated ERK is capable of translocating to the nucleus, where it regulates gene expression by activating transcription factors.


The polyclonal antibody reacts with MEK 1/2. MEK 1 and MEK 2 are integral components of the MAP kinase cascade, an important pathway for cell growth and differentiation.

Regulatory Status


Synthetic peptide (coupled with KLH) derived from aminoacid sequence 33-53 of human MAPK Kinase 1. The immunogen sequence is highly conserved within species (human, mouse, rat, hamster, bovine etc.).

Species Reactivity:

  • Human

Negative Species:


  • Western Blotting
    Recommended dilution: 0.5 μg/ml
    Positive material: RAJI human Burkitt lymphoma cell line
    Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with non-reducing/reducing Laemmli SDS-PAGE sample buffer. Boil for 5 min.
    Application note: Both reducing and non-reducing conditions. Reducing conditions are recommended.
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003 Jul;17(7):1263-93. [Abstract]
  • *Park JI, Strock CJ, Ball DW, Nelkin BD: The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol. 2003 Jan;23(2):543-54. [Abstract] [Full Text]
  • *Sundaram MV: RTK/Ras/MAPK signaling. WormBook. 2006 Feb 11;:1-19. [Abstract] [Full Text]
  • *McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. [Abstract]
  • *Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, Khavari PA. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell. 2007 Apr;12(4):615-29. [Abstract]
  • *Park ER, Eblen ST, Catling AD: MEK1 activation by PAK: a novel mechanism. Cell Signal. 2007 Jul;19(7):1488-96. [Abstract] [Full Text]
  • Product Specific References

  • *Sikorski K, Mehta A, Inngjerdingen M, Thakor F, Kling S, Kalina T, Nyman TA, Stensland ME, Zhou W, de Souza GA, Holden L, Stuchly J, Templin M, Lund-Johansen F: A high-throughput pipeline for validation of antibodies. Nat Methods. 2018 Nov;15(11):909-912. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    MEK 1/2
    Fig. 1.

    Fig. 1. Western Blotting analysis (reducing conditions) of human MEK1/2 in whole cell lysate of RAJI human Burkitt lymphoma cell line using polyclonal anti-MEK1/2 antibody.

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy